Surrogate endpoints for the treatment of venous leg ulcers

Journal of Investigative Dermatology

Volumn 119, Issue 6, 2002, Pages 1420-1425

  Gelfand, Joel M ^a,b   Hoffstad, Ole ^a   Margolis, David J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 2 Maloney Building ^*  (United States)

Author keywords

Epidemiologic; Leg ulcer; Outcome assessment; Randomized controlled trials; Varicose ulcer

Indexed keywords

ALGORITHM; ARTICLE; BONE; CONTROLLED STUDY; DISEASE MARKER; EVALUATION; HUMAN; LEG ULCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; TENDON; TREATMENT OUTCOME; WOUND HEALING;

EID: 0036911403     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2002.19629.x     Document Type: Article

References (35)

1. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H: Statistical validation of surrogate endpoints: Problems and proposals. Drug Info J 34:447-454, 2000
2. De Gruttola VG, Clax P, DeMets DL, et al: Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health workshop. Control Clin Trials 22:485-502, 2001
3. Doucette MM, Fylling C, Knighton DR: Amputation prevention in a high-risk population through comprehensive wound-healing protocol. Arch Phys Med Rehabil 70:780-785, 1989
4. Ellenberg SS: Surrogate endpoints: The debate goes on. Pharmacoepidemiol Drug Saf 10:493-496, 2001
5. FDA ICH E9: E9 Statistical Principles for Clinical Trials. www. FDA.gov September, 1998
6. FDA Wound Healing Clinical Focus Group: Guidance for industry. Chronic cutaneous ulcer and burn wounds-developing products for treatment (Draft-Not for implementation). Wound Repair Regeneration 9:258-268, 2001
7. Fleming TR, DeMets DL: Surrogate endpoints in clinical trials: Are we being misled? Ann Intern Med 125:605-613, 1996
8. Freedman LS, Graubard BI, Schatzkin A: Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167-178, 1992
9. Fylling CP, Knighton DR: Amputation in the diabetic population incidence, causes, cost, treatment, and prevention. J Enterostomal Ther 16:247-255, 1989
10. Gilman TH: Parameter for the measurement of wound closure. Wounds 3:95-101, 1990
11. Gross EA, Wood CR, Lazarus GS, Margolis DJ: Venous leg ulcers. an analysis of underlying disease. Br J Dermatol 129:270-274, 1993
12. Hosmer DW, Lemeshow S: Appl Logistic Regression 2nd Edition. John Wiley and Sons, Inc: Newyork. 2000
13. Hotta SS, Holohan TV: Health Technology Review. Procuren-a Platelet Derived Wound Healing Formula. 1-4, 1992
14. Kantor J, Margolis DJ: From clinical trials to clinical practice: The efficacy and prognostic value of simple wound measurements. Arch Dermatol 134:1571-1574, 1998
15. Kantor J, Margolis DJ: Efficacy and prognostic value of simple wound measurements. Arch Dermatol 134:1571-1574, 1999
16. Kantor J, Margolis DJ: A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks. Br J Dermatol 142:960-964, 2000a
17. Kantor J, Margolis DJ: The accuracy of using a wound care specialty clinic database to study diabetic neuropathic foot ulcers. Wound Repair Regen 8:169-173, 2000
18. Knighton DR, Fiegel VD, Doucette MM, Fylling CP, Cerra F: The use of topically applied platelet growth factors in chronic nonhealing wounds: A review. Wounds 1:71-78, 1989
19. Knighton DR, Fylling CP, Fiegel VD, Cerra F: Amputation prevention in an independently reviewed at-risk diabetic population using a comprehensive wound care protocol. Am J Surg 160:466-471, 1990a
20. Knighton DR, Citresi K, Flegel VD, Austin LL, Butler EL: Stimulation of repair in chronic, nonhealing cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet 170:56-60, 1990b
21. Lindblad WJ: Welcome (?) guidance from the Food and Drug Administration. Wound Repair Regeneration 9:257, 2001
22. Lonn E: The use of surrogate endpoints in clinical trials: Focus on clinical trials in cardiovascular diseases. Pharmacoepidemiol Drug Saf 10:497-508, 2001
23. Margolis D, Gross E, Wood CR, Lazarus GS: Planimetric rate of healing in venous ulcers of the leg treated with pressure bandage and hydrocolloid dressing. J Am Acad Dermatol 28:418-421, 1993
24. Margolis DJ, Kantor J, Berlin JA: Healing of diabetic neuropathic foot ulcers receiving standard treatment: a meta analysis. Diabetes Care 22:692-695, 1999a
25. Margolis DJ, Berlin JA, Strom BL: Risk factors associated with the failure of a venous leg ulcer to heal. Arch Dermatol 135:920-926, 1999b
26. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA: Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 24:483-488, 2001
27. Mayfield JA, Reiber GE, Nelson RG, Greene T: A foot risk classification system to predict diabetic amputation in Pima Indians. Diabetes Care 19:704-709, 1996
28. Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL: Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes 40:1305-1313, 1991
29. Prentice RL: Surrogate endpoints in clinical trials definitions and operational criteria. Stat Med 8:431-440, 1989
30. Pstay BM, Weiss NS, Furberg CD, et al: Surrogate endpoints, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 282:786-795, 1999
31. Robson MC, Maggi SP, Smith PD,Wassermann RJ, Mosiello GC, Hill DP, Cooper DM: Original articles ease of wound closure as an endpoint of treatment efficacy. Wound Repair Regeneration 7:90-96, 1999
32. Robson MC, Hill DP, Woodske ME, Steed DL: Wound healing trajectories as predictors of effectiveness of therapeutic agents. Arch Surg 135:773-777, 2000
33. Steyerberg EW, Harrell FE, Borsboom GJJM, Eijkemans MJC, Vergouwe Y, Habbema DF: Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54:774-781, 2001
34. Tallman P, Muscare E, Carson P, Eaglstein WH, Falanga V: Initial rate of healing predicts complete healing of venous ulcers. Arch Dermatol 133: 1231-1234, 1997
35. Temple R: Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282:790-795, 1999